Valuation: Rein Therapeutics Inc.

Market Cap 53.9M 48M 44.44M 40.25M 75.71M 5.09B 76.74M 532M 209M 2.67B 202M 198M 8.52B P/E 2026 *
-1.36x
P/E 2027 * -1.34x
Enterprise Value 53.9M 48M 44.44M 40.25M 75.71M 5.09B 76.74M 532M 209M 2.67B 202M 198M 8.52B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.98%
Yield 2026 *
-
Yield 2027 * -
1 day+4.99%
1 week-17.20%
Current month-22.29%
1 month-21.90%
3 months-25.97%
6 months-65.86%
Current year-46.14%
1 week 0.54
Extreme 0.5432
0.67
1 month 0.54
Extreme 0.540101
0.9
Current year 0.54
Extreme 0.540101
2.1
1 year 0.54
Extreme 0.540101
2.18
3 years 0.54
Extreme 0.540101
7.42
5 years 0.54
Extreme 0.540101
19.82
10 years 0.54
Extreme 0.540101
309.6
Manager TitleAgeSince
Chief Executive Officer 60 2024-03-10
Director of Finance/CFO 64 2024-05-15
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 70 2013-05-31
Chairman 71 2023-10-30
Director/Board Member 60 2024-03-10
Date Insider Type Main position Quantity % Market Cap. Importance
5/27/26 Buy

Chairman

4,500 0.0058%
5/8/26 Free

Chief Executive Officer

-150,000 0.1922%
11/14/25
Voss Capital LP
BuyCompany 104,183 0.4424%
Change 5-day change 1-year change 3-year change Capi.($)
+4.99%-17.20%-51.19%-50.41% 51.34M
-0.21%-6.36%+49.00%+74.13% 66.34B
-0.22%+10.10%+12.77%+87.32% 52.92B
+0.82%+9.46%+7.75%+73.53% 54.82B
+3.28%+6.12%+30.46%+50.05% 44.09B
+0.51%+10.71%+21.30%+133.92% 43.72B
-1.15%+3.10%+259.71%+594.60% 42.13B
+0.10%+9.96%+17.15%+59.33% 33.96B
-1.30%-3.61%+37.37%+7.16% 26.17B
+0.69%+6.07%+31.89%+26.94% 23.37B
Average +0.75%+2.19%+41.62%+105.66% 38.76B
Weighted average by Cap. +0.32%+4.66%+51.27%+127.75%

Financials

2026 *2027 *
Net sales - -
Net income -29.15M -25.96M -24.04M -21.77M -40.95M -2.75B -41.51M -288M -113M -1.45B -109M -107M -4.61B -37.01M -32.96M -30.52M -27.64M -52M -3.5B -52.7M -365M -143M -1.84B -139M -136M -5.85B
Net Debt - -
Projected Income Statement - Annual - Rein Therapeutics Inc.
Logo Rein Therapeutics Inc.
Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Company's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
Employees
10
Date Price Change Volume
26-10-21 US$0.6248 +4.99% 265,749
26-10-20 US$0.5951 +7.81% 296,443
26-10-19 US$0.5520 -6.49% 502,154
26-10-16 US$0.5903 -6.00% 372,098
26-10-15 US$0.6280 +7.17% 1,372,904
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Rein Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.6248USD
Average target price
6.000USD
Spread / Average Target
+860.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Rein Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. RNTX Stock